

**Supplementary Table 1.** Baseline characteristics of patients treated with tildrakizumab divided by previous treatment. DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area and Severity Index; PsO, psoriasis; SD, standard deviation.

<b>Characteristic</b>	<b>Biologic naive</b>	<b>Biologic experienced</b>
	<b><i>n=27</i></b>	<b><i>n=27</i></b>
Age (years), mean $\pm$ SD	47.7 $\pm$ 13.4	52.9 $\pm$ 15.2
Male, <i>n</i> (%)	19 (70.4)	11 (40.7)
Weight (kg), mean $\pm$ SD	71.4 $\pm$ 9.4	74.6 $\pm$ 15.5
BMI (kg/m <sup>2</sup> ), mean $\pm$ SD	24.8 $\pm$ 2.0	26.1 $\pm$ 4.2
Family history of PsO, <i>n</i> (%)	6 (22.2)	9 (33.3)
Disease duration (years), mean $\pm$ SD	17.8 $\pm$ 11.7	26.7 $\pm$ 16.4
PASI score, mean $\pm$ SD	19.6 $\pm$ 9.7	19.2 $\pm$ 12.1
DLQI score, mean $\pm$ SD	18.4 $\pm$ 6.1	18.7 $\pm$ 7.6